British Journal of Neurosurgery · 1988 · 25 citations · 24 references
MedicineNuclear MedicineOncologyMonoclonal AntibodiesRadiobiologyRadionuclide TherapyAntibody CharacterizationBrain TumorsDiagnostic Monoclonal AntibodiesImmunohistochemistryMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesAdministration Of Monoclonal AntibodiesAntibody RadiopharmaceuticalsAntibody-based Radionuclide TherapyMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyMonoclonal Antibody InfusionNeoplastic MeningitisPineal Tumors
A monoclonal antibody (UJ181.4) was labelled with 131I and given intrathecally to a patient who was critically ill with neoplastic meningitis due to a disseminated pineoblastoma. The target antigen had first been demonstrated on tumour cells by immunocytological testing of cerebrospinal fluid (CSF). As a preparation for therapy, a test dose of 131I-UJ181.4 antibody was given simultaneously with a control antibody labelled with 125I. Good evidence of in vivo immunolocalization was obtained by external gamma counting and by analysis of the radiolabels on centrifuged CSF cells. Specificity ratios of between 10:1 and 20:1 were obtained by these methods. A single relatively small therapeutic dose of 131-I (870 MBq) given by the intrathecal route, resulted in a marked clinical improvement and sustained remission for 22 months.
24
Continuous cultures of fused cells secreting antibody of predefined specificity
Georges Köhler, César Milstein · Nature · 1975 · 17.2K citations
Pharmacy, Cell Biology, Immunology +11
L Wickstrom, K Pettersson · PubMed · 1964 · 1.2K citations
Joyce Taylor‐Papadimitriou, Jerry A. Peterson, J. Arklie et al. · International Journal of Cancer · 1981 · 604 citations